GlenRock Group

About

Portfolio · 29

MSICS Pharma

GMP Naturally Sourced Psilocybin Pioneers

1 round $3.6M committed Latest: 2026-05

Treetoscope

Direct Plant-sensing Technology for Irrigation Management

1 round $7.0M committed Latest: 2024-03

Quris-AI

AI-based Drug Development Platform

2 rounds $28.0M committed Latest: 2022-12

Karamba Security

Embedded Security for Connected Systems

4 rounds $27.0M committed Latest: 2021-12

Cylus

Railway Cybersecurity Solutions

2 rounds $42.0M committed Latest: 2021-12

Lydus Medical

Automated Microvascular Anastomosis for Ultrasmall Vessels

1 round $2.7M committed Latest: 2021-05

Magnus Metal

Digital Casting Process for Industrial Volume Production of Metal Alloys

1 round Latest: 2021-04

270Surgical

Specialty Laparoscopic System for Wide Cavity Visualization

1 round Latest: 2021-01

Nurami Medical

Modernizing Soft Tissue Repair

1 round $6.0M committed Latest: 2020-11

NONAGON

Virtual Care Solution

1 round Latest: 2020-10

Cardiovalve

Cardiovascular Replacement Devices for Minimally Invasive Surgery

1 round $40.0M committed Latest: 2020-08

Model9

Cloud Data Management for Mainframe Computer Environments

2 rounds $12.5M committed Latest: 2020-02

Capitalise

Text-based Trading Analysis and Automation

1 round $9.5M committed Latest: 2019-08

IM Cannabis

High-Quality Medical Cannabis

1 round $9.1M committed Latest: 2018-05

Idomoo

AI-powered Personalized and Interactive Video Platform for Data-driven Customer Engagement

1 round $3.0M committed Latest: 2018-01

Cellium Technologies

Residential and Enterprise Wi-Fi Solution

1 round Latest: 2018-01

Ecoppia

Water-free Robotic Cleaning for Photovoltaic Panels

1 round $13.0M committed Latest: 2017-11

CyberX

IIoT and ICS Cyber-security Platform

2 rounds $11.0M committed Latest: 2016-08

Veloryx

Integrated Homeland Security Solutions

2 rounds $7.5M committed Latest: 2016-03

LifeBond

Biosurgery Products for Preventing Postoperative Complications

3 rounds $48.5M committed Latest: 2015-08

PV Nano Cell

Single-crystal Conductive Nano Inks

1 round $1.3M committed Latest: 2014-12

Smart Medical Systems

Medical Devices for GI Endoscopy

1 round $6.5M committed Latest: 2014-04

VBL Therapeutics

Targeted Therapies for Immune-inflammatory Diseases

1 round $40.0M committed Latest: 2010-10

DigiFlex

Inkjet-based Computer-to-Plate Printing Technology

1 round $100K committed Latest: 2010-02

Mobile Max Technologies

Mobile UC and FMC applications

1 round $5.0M committed Latest: 2010-02

Quigo

An Ad-targeting Network that Enables Advertisers to Buy Web Ads

1 round $30.0M committed Latest: 2007-06

Human Monitoring

Image- and Video-processing Technologies

1 round $1.0M committed Latest: 2007-01

Mobileye

Autonomous Driving and Driver-assist Technologies

1 round $15.0M committed Latest: 2006-05

Rosetta Genomics

MicroRNA-based Diagnostic Tests for Personalized Medicine

1 round $6.0M committed Latest: 2005-09

Investment activity

14 portfolio exits on record.

Q&A

What are GlenRock Group's most recent exits?

GlenRock Group has two recent exits: Capitalise was acquired by Kraken in August 2025, and Model9 was acquired by BMC Software in April 2023.

Which sectors does GlenRock Group primarily invest in?

GlenRock Group shows a strong concentration in Health Tech & Life Sciences, with 12 portfolio companies, and Industrial Technologies, with 5 portfolio companies.

Can you name some of GlenRock Group's portfolio companies in the Cyber Security sector?

GlenRock Group's portfolio includes CyberX, which was acquired by Microsoft in June 2020, and Cylus, a railway cybersecurity solutions provider.

What is GlenRock Group's investment focus according to their thesis?

GlenRock Group is a single-family office that focuses on Life Sciences, Advanced Technology, and Private Equity, taking an active and long-term role in their portfolio companies.

Which public exits has GlenRock Group had in recent years?

GlenRock Group has seen several public exits, including Teads, which went public on NASDAQ in July 2021 with a valuation of $1.25 billion, and Idomoo, which went public on TASE in June 2021 with a valuation of $105.83 million.

Who are the key personnel at GlenRock Group?

The key personnel at GlenRock Group include Leon Recanati, the Founder & CEO, and Asaf Iram, a Managing Partner.

Has GlenRock Group had any notable exits in the Health Tech & Life Sciences sector?

Yes, Cardiovalve was acquired by Venus Medtech for $150 million in March 2022, and LifeBond was acquired by Bard Medical for $60 million in January 2020.

What is the typical investment stage for GlenRock Group?

GlenRock Group invests across various stages, including Seed, A Round, B Round, C Round, D Round, E Round, F Round, and G Round.